A method to identify new molecular markers for assessing minimal residual disease in acute leukemia patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F13%3A10140043" target="_blank" >RIV/00179906:_____/13:10140043 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/28205227:_____/13:#0000002 RIV/00216208:11120/13:43907564 RIV/00064173:_____/13:#0000326 RIV/00669806:_____/13:10140043

Výsledek na webu

<a href="http://ac.els-cdn.com/S0145212613001951/1-s2.0-S0145212613001951-main.pdf?_tid=c4ceda60-a2a4-11e3-b071-00000aab0f01&acdnat=1393831611_c699c8ed4f9c923bc5c17ac2c5018ce3" target="_blank" >http://ac.els-cdn.com/S0145212613001951/1-s2.0-S0145212613001951-main.pdf?_tid=c4ceda60-a2a4-11e3-b071-00000aab0f01&acdnat=1393831611_c699c8ed4f9c923bc5c17ac2c5018ce3</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.leukres.2013.06.009" target="_blank" >10.1016/j.leukres.2013.06.009</a>

Jazyk výsledku

angličtina

Název v původním jazyce

A method to identify new molecular markers for assessing minimal residual disease in acute leukemia patients

Popis výsledku v původním jazyce

Acute leukemias (AL) comprise a heterogeneous group of hematologic malignancies, and individual patient responses to treatment can be difficult to predict. Monitoring of minimal residual disease (MRD) is thus very important and holds great potential forimproving treatment strategies. Common MRD targets include recurrent cytogenetic abnormalities and mutations in important hematological genes; unfortunately well-characterized targets are lacking in many AL patients. Here we demonstrate a technical approach for the identification and mapping of novel clone-specific chromosomal abnormalities down to the nucleotide level. We used molecular cytogenetics, chromosome microdissection, amplification of the microdissected material, and next-generation sequencing to develop PCR-based MRD assays based on unique breakpoint sequences

Název v anglickém jazyce

A method to identify new molecular markers for assessing minimal residual disease in acute leukemia patients

Popis výsledku anglicky

Acute leukemias (AL) comprise a heterogeneous group of hematologic malignancies, and individual patient responses to treatment can be difficult to predict. Monitoring of minimal residual disease (MRD) is thus very important and holds great potential forimproving treatment strategies. Common MRD targets include recurrent cytogenetic abnormalities and mutations in important hematological genes; unfortunately well-characterized targets are lacking in many AL patients. Here we demonstrate a technical approach for the identification and mapping of novel clone-specific chromosomal abnormalities down to the nucleotide level. We used molecular cytogenetics, chromosome microdissection, amplification of the microdissected material, and next-generation sequencing to develop PCR-based MRD assays based on unique breakpoint sequences

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia Research

ISSN

0145-2126

e-ISSN

—

Svazek periodika

37

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

11

Strana od-do

1363-1373

Kód UT WoS článku

000324099100031

EID výsledku v databázi Scopus

—